Shigeki Mitsuoka

880 total citations
55 papers, 645 citations indexed

About

Shigeki Mitsuoka is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Shigeki Mitsuoka has authored 55 papers receiving a total of 645 indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Pulmonary and Respiratory Medicine, 40 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Shigeki Mitsuoka's work include Lung Cancer Treatments and Mutations (39 papers), Lung Cancer Research Studies (21 papers) and Colorectal Cancer Treatments and Studies (12 papers). Shigeki Mitsuoka is often cited by papers focused on Lung Cancer Treatments and Mutations (39 papers), Lung Cancer Research Studies (21 papers) and Colorectal Cancer Treatments and Studies (12 papers). Shigeki Mitsuoka collaborates with scholars based in Japan and United States. Shigeki Mitsuoka's co-authors include Tatsuo Kimura, Kazuto Hirata, Naruo Yoshimura, Shinzoh Kudoh, Tomohiro Suzumura, Tomoya Kawaguchi, Kazuhisa Asai, Naoki Yoshimoto, Toshiyuki Nakai and Tetsuya Watanabe and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Shigeki Mitsuoka

54 papers receiving 634 citations

Peers

Countries citing papers authored by Shigeki Mitsuoka

Since Specialization

Citations

This map shows the geographic impact of Shigeki Mitsuoka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shigeki Mitsuoka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shigeki Mitsuoka more than expected).

Fields of papers citing papers by Shigeki Mitsuoka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shigeki Mitsuoka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shigeki Mitsuoka. The network helps show where Shigeki Mitsuoka may publish in the future.

Co-authorship network of co-authors of Shigeki Mitsuoka

This figure shows the co-authorship network connecting the top 25 collaborators of Shigeki Mitsuoka. A scholar is included among the top collaborators of Shigeki Mitsuoka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shigeki Mitsuoka. Shigeki Mitsuoka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Vimentin expression correlates with immune checkpoint inhibitor efficacy in non–small cell lung cancer 2023 ·Cancer ·Kenji Nakahama, (unknown), Naoki Yoshimoto, Mitsuru Fukui, Akira Sugimoto, (unknown), K. Ogawa, Kenji Sawa, (unknown), Hiroyasu Kaneda, Shigeki Mitsuoka, Tetsuya Watanabe, Kazuhisa Asai, Tomoya Kawaguchi	2
2	Clinical significance of KL-6 in immune-checkpoint inhibitor treatment for non-small cell lung cancer 2023 ·Cancer Chemotherapy and Pharmacology ·Kenji Nakahama, (unknown), Naoki Yoshimoto, Mitsuru Fukui, Akira Sugimoto, (unknown), (unknown), Kenji Sawa, (unknown), Hiroyasu Kaneda, Shigeki Mitsuoka, (unknown), Kazuhisa Asai, Tomoya Kawaguchi	4
3	RBM17 Expression Is Associated With the Efficacy of ICI Monotherapy in NSCLC With Low PD-L1 Expression 2023 ·Anticancer Research ·(unknown), Masakazu Yashiro, Naoki Yoshimoto, (unknown), Akira Sugimoto, Kenji Nakahama, (unknown), (unknown), Kenji Sawa, (unknown), Hiroyasu Kaneda, Shigeki Mitsuoka, Kazuhiro Yamada, (unknown), (unknown), (unknown), Akila Mayeda, Tomoya Kawaguchi	3
4	Lack of Association Between Immunotherapy and Improvement of Survival for Non-small Cell Lung Cancer Patients With Hemodialysis: A Nationwide Retrospective Cohort Study 2023 ·Clinical Lung Cancer ·Kenji Sawa, (unknown), Takumi Imai, Akira Sugimoto, (unknown), Koichi Ogawa, Kenji Nakahama, (unknown), (unknown), Hiroyasu Kaneda, Shigeki Mitsuoka, Tomoya Kawaguchi, Ayumi Shintani	2
5	The Impact of Estrogen Receptor Expression on Mutational Status in the Evolution of Non-Small Cell Lung Cancer 2022 ·Clinical Lung Cancer ·(unknown), Hiroyasu Kaneda, Yasuhiro Koh, Akihiro Tamiya, Shun‐ichi Isa, Akihito Kubo, (unknown), (unknown), Kenji Sawa, Naoki Yoshimoto, Shigeki Mitsuoka, Tomoya Kawaguchi	2
6	Tumor microenvironment disparity in multiple primary lung cancers: Impact of non-intrinsic factors, histological subtypes, and genetic aberrations 2021 ·Translational Oncology ·(unknown), Kenji Sawa, Jun Oyanagi, (unknown), Mitsuru Fukui, (unknown), (unknown), (unknown), Tomohiro Suzumura, Tetsuya Watanabe, Hiroyasu Kaneda, Shigeki Mitsuoka, Kazuhisa Asai, Noritoshi Nishiyama, Masahiko Ohsawa, Nobuyuki Yamamoto, Yasuhiro Koh, Tomoya Kawaguchi	11
7	Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non–small cell lung cancer patients with asymptomatic brain metastases 2021 ·Investigational New Drugs ·Hiroyasu Kaneda, Kenji Sawa, Haruko Daga, (unknown), Yuki Nakatani, Shinji Atagi, Kyoichi Okishio, (unknown), (unknown), (unknown), Kenji Nakahama, (unknown), Shigeki Mitsuoka, Tomoya Kawaguchi	3
8	Mutational landscape of multiple primary lung cancers and its correlation with non-intrinsic risk factors 2021 ·Scientific Reports ·(unknown), Jun Oyanagi, Kenji Sawa, Mitsuru Fukui, (unknown), (unknown), (unknown), Tomohiro Suzumura, Tetsuya Watanabe, Hiroyasu Kaneda, Shigeki Mitsuoka, Kazuhisa Asai, Masahiko Ohsawa, Nobuyuki Yamamoto, Yasuhiro Koh, Tomoya Kawaguchi	18
9	Early-onset meningitis associated with atezolizumab treatment for non-small cell lung cancer: case report and literature review 2020 ·Investigational New Drugs ·(unknown), Hiroyasu Kaneda, (unknown), (unknown), (unknown), (unknown), Kenji Sawa, Tomohiro Suzumura, Tetsuya Watanabe, Shigeki Mitsuoka, Kazuhisa Asai, Tomoya Kawaguchi	5
10	Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor‐tyrosine kinase inhibitors in patients with EGFR‐mutant non‐small cell lung cancer 2019 ·Cancer Science ·(unknown), Kenji Sawa, Mitsuru Fukui, Jun Oyanagi, (unknown), (unknown), Tomohiro Suzumura, Tetsuya Watanabe, Hiroyasu Kaneda, Shigeki Mitsuoka, Kazuhisa Asai, Tatsuo Kimura, Nobuyuki Yamamoto, Yasuhiro Koh, Tomoya Kawaguchi	31
11	Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors 2019 ·Lung Cancer ·(unknown), Kenji Sawa, Mitsuru Fukui, Jun Oyanagi, Naoki Yoshimoto, Tomohiro Suzumura, Tetsuya Watanabe, Hiroyasu Kaneda, Shigeki Mitsuoka, Kazuhisa Asai, Tatsuo Kimura, Nobuyuki Yamamoto, Kazuto Hirata, Yasuhiro Koh, Tomoya Kawaguchi	9
12	Efficacy and safety of ultrasound (US) guided percutaneous needle biopsy for peripheral lung or pleural lesion: comparison with computed tomography (CT) guided needle biopsy 2019 ·Journal of Thoracic Disease ·Norio Yamamoto, Tetsuya Watanabe, Kazuhiro Yamada, Toshiyuki Nakai, Tomohiro Suzumura, (unknown), Naoki Yoshimoto, Kanako Sato, Hidenori Tanaka, Shigeki Mitsuoka, (unknown), Tatsuo Kimura, Hiroshi Kanazawa, Kazuto Hirata, Tomoya Kawaguchi	46
13	PIK3CA mutation as a distinctive genetic feature of non-small cell lung cancer with chronic obstructive pulmonary disease: A comprehensive mutational analysis from a multi-institutional cohort 2017 ·Lung Cancer ·Kenji Sawa, Yasuhiro Koh, Tomoya Kawaguchi, (unknown), Kazuhisa Asai, Shigeki Mitsuoka, Tatsuo Kimura, Naruo Yoshimura, Naoki Yoshimoto, Akihito Kubo, Hideo Saka, Akihide Matsumura, Hideki Wanibuchi, Nobuyuki Yamamoto, Noritoshi Nishiyama, Kazuto Hirata	19
14	Plasma RANTES, IL-10, and IL-8 levels in non–small-cell lung cancer patients treated with EGFR-TKIs 2013 ·BMC Research Notes ·(unknown), Tatsuo Kimura, Shinzoh Kudoh, Tomohiro Suzumura, (unknown), (unknown), Shigeki Mitsuoka, (unknown), Toshiyuki Nakai, Naruo Yoshimura, Yukimi Kira, Kazuto Hirata	21
15	Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer 2012 ·BMC Cancer ·Tomohiro Suzumura, Tatsuo Kimura, Shinzoh Kudoh, (unknown), (unknown), (unknown), Hidenori Tanaka, Shigeki Mitsuoka, Naruo Yoshimura, Yukimi Kira, Toshiyuki Nakai, Kazuto Hirata	40
16	Dose Escalation and Feasibility Study of Amrubicin Combined With Cisplatin in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer 2012 ·American Journal of Clinical Oncology ·Naruo Yoshimura, Tatsuo Kimura, Shigeki Mitsuoka, (unknown), Yoshihiro Tochino, Kazuhisa Asai, (unknown), Kazuto Hirata, Shinzoh Kudoh	1
17	Reaction of plasma hepatocyte growth factor levels in non‐small cell lung cancer patients treated with EGFR‐TKIs 2010 ·International Journal of Cancer ·Hidenori Tanaka, Tatsuo Kimura, Shinzoh Kudoh, Shigeki Mitsuoka, Tetsuya Watanabe, Tomohiro Suzumura, Keisei Tachibana, Masayuki Noguchi, Seiji Yano, Kazuto Hirata	20
18	Phase II Study of Docetaxel and Carboplatin in Elderly Patients with Advanced Non-small Cell Lung Cancer 2009 ·Journal of Thoracic Oncology ·Naruo Yoshimura, Shinzoh Kudoh, Tatsuo Kimura, Shigeki Mitsuoka, (unknown), Yoshihiro Tochino, Kazuhisa Asai, (unknown), (unknown), Takashi Yana, Kazuto Hirata	17
19	Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses 2006 ·Cancer Chemotherapy and Pharmacology ·Kenji Tamura, Kazuhiko Nakagawa, Takayasu Kurata, Taroh Satoh, (unknown), Koji Takeda, Shigeki Mitsuoka, Naruo Yoshimura, Shinzoh Kudoh, Shunichi Negoro, Masahiro Fukuoka	30
20	A phase II study of continuous concurrent thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small cell lung cancer 2002 ·Lung Cancer ·Shinji Atagi, Masaaki Kawahara, Shigeto Hosoe, Mitsumasa Ogawara, Tomoya Kawaguchi, Kyoichi Okishio, (unknown), (unknown), Shigeki Mitsuoka, Masanori Akira	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact